Phase 3 Success: Nefecon Shows Promise in Treating IgA Nephropathy, Filing Planned for Early 2021
Key Insights
Calliditas Therapeutics' Nefecon (search) demonstrated significant efficacy in Phase 3 trial, showing 31% reduction in proteinuria compared to 5% in placebo for IgA nephropathy (search) treatment.
The drug showed favorable safety profile consistent with budesonide, with key secondary endpoint demonstrating 7% treatment benefit in estimated glomerular filtration rate versus placebo.
Company plans FDA filing for accelerated approval in Q1 2021, followed by EMA submission in H2, targeting 130,000-150,000 potential patients in US market.
Swedish biotech Calliditas Therapeutics has achieved a significant milestone in addressing the unmet needs of IgA nephropathy (search) (IgAN) patients, with its novel drug Nefecon (search) demonstrating positive results in a pivotal Phase 3 clinical trial.
The global Phase 3 NefIgArd trial, involving 199 patients, met its primary endpoint with compelling efficacy data. Patients receiving 16 mg of Nefecon (search) showed a 31% mean reduction in urine protein creatinine ratio (UPCR) from baseline, significantly outperforming the placebo group's 5% reduction. This resulted in a notable 27% mean reduction at 9 months compared to placebo.
Clinical Benefits and Disease Impact
IgA nephropathy (search), affecting 130,000-150,000 people in the United States, currently has no approved treatments. The condition originates from overproduction of antibodies in the small intestine's lining, which subsequently accumulate in the kidneys, leading to severe complications.
Nefecon (search)'s innovative approach targets the Peyer's patches (search), which are hyperactive in IgAN patients. The drug is a specialized formulation of budesonide, an established immunology medication, designed to address the root cause of the disease.
Key Secondary Endpoints and Safety Profile
The trial demonstrated significant improvements in estimated glomerular filtration rate (eGFR), a crucial marker of kidney function. The treatment arm showed stabilization while the placebo group experienced a 7% decline, resulting in a 7% treatment benefit at nine months.
"Calliditas has been a pioneer in IgAN for many years, and we are excited to be the only company to have reported out a positive phase 3 trial in this indication," stated CEO Renee Aguiar-Lucander. "This result brings hope to thousands of patients who today have no approved treatment alternatives."
Regulatory Strategy and Market Potential
The company plans to submit an accelerated approval application to the FDA in Q1 2021, followed by a conditional approval submission to the European Medicines Agency in the second half of the year. Both approvals will require confirmatory data from an expanded patient cohort for permanent market authorization.
Calliditas, which raised $81 million in its 2018 IPO, intends to commercialize Nefecon (search) independently in the US market while pursuing collaborative partnerships for other regions. The company's position as a frontrunner in IgAN treatment is particularly significant, with only one potential competitor, US biotech Aravive, currently in mid-stage clinical development.